Table 2.
Response rate and safety of lenalidomide in DLBCL
| Primary outcomes | Lenalidomide group | Control group | No of studies | No. of patients | I2 (%) | P value for heterogeneity | RR (95%CI) | P value for effects model | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Pooled rate (%, 95%CI) | I2 (%) | Pooled rate (%, 95%CI) | I2 (%) | |||||||
| Response rate | ||||||||||
| ORR | 67.0 (45.7, 85.3) | 96.5 | 56.9 (31.4, 80.6) | 97.5 | 6 | 1938 | 61.2 | 0.024 | 1.09 (0.99, 1.20) | 0.080 |
| CRR | 47.7 (28.5, 67.2) | 94.5 | 37.8 (16.7, 61.5) | 96.1 | 6 | 1938 | 0 | 0.468 | 1.11 (1.03, 1.20) | 0.008 |
| PRR | 16.3 (10.6, 23.0) | 87.7 | 15.6 (10.1, 21.9) | 85.7 | 6 | 1938 | 0 | 0.423 | 0.96 (0.79; 1.17) | 0.674 |
| Safety | ||||||||||
| Neutropenia | 48.3 (37.5, 59.1) | 86.6 | 31.7 (19.7, 44.9) | 94.6 | 6 | 1938 | 86.0 | < 0.001 | 1.56 (1.15, 2.11) | 0.004 |
| Thrombocytopenia | 13.7 (5.7, 24.2) | 95.2 | 10.5 (1.9, 24.1) | 94.8 | 6 | 1938 | 75.5 | 0.001 | 1.55 (0.71, 3.37) | 0.272 |
| Anemia | 17.3 (9.9, 26.1) | 81.7 | 16.0 (8.3, 25.5) | 82.8 | 5 | 1293 | 53.9 | 0.070 | 1.21 (0.79, 1.87) | 0.383 |
| Febrile neutropenia | 11.9 (5.2, 20.6) | 87.1 | 5.8 (1.8, 11.5) | 81.7 | 5 | 1293 | 0 | 0.891 | 1.81 (1.31, 2.49) | < 0.001 |
Italic values indicate P < 0.05
ORR overall response rate, CRR complete response rate, PRR partial response rate, 95%CI 95% confidence interval, RR relative risk